Alpha 2.0
Login Register
» Articles » PMID: 32762494

Recovery from COVID-19 in a B-cell-depleted Multiple Sclerosis Patient

Overview
Journal Mult Scler
Publisher Sage Publications
Specialty Neurology
Date 2020 Aug 9
PMID 32762494
Citations 29
Authors
Hannah Wurm
Kate Attfield
Astrid Kn Iversen
Ralf Gold
Lars Fugger
Aiden Haghikia
Affiliations
Soon will be listed here.
Abstract

Approximately 200,000 multiple sclerosis (MS) patients worldwide receive B-cell-depleting immunotherapy with rituximab (anti-CD20), which eliminates the ability to generate an antibody response to new infections. As severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific antibodies might help viral clearance, these patients could be at risk of severe complications if infected. Here, we report on an MS patient who had received rituximab for ~3 years. The patient was examined 5 days before the onset of coronavirus disease 2019 (COVID-19) symptoms and was admitted to the hospital 2 days after. She recovered 14 days after symptom onset despite having a 0% B lymphocyte count and not developing SARS-CoV-2 immunoglobulin G (IgG) antibodies.

Citing Articles

Cytokine profile of anti-spike CD4T cells predicts humoral and CD8T cell responses after anti-SARS-CoV-2 mRNA vaccination.

Benhamouda N, Besbes A, Bauer R, Mabrouk N, Gadouas G, Desaint C iScience. 2024; 27(8):110441.

PMID: 39104410 PMC: 11298648. DOI: 10.1016/j.isci.2024.110441.

Early protective effect of a ("pan") coronavirus vaccine (PanCoVac) in Roborovski dwarf hamsters after single-low dose intranasal administration.

Abdelaziz M, Raftery M, Weihs J, Bielawski O, Edel R, Koppke J Front Immunol. 2023; 14:1166765.

PMID: 37520530 PMC: 10372429. DOI: 10.3389/fimmu.2023.1166765.

Immune response to BNT162b2 SARS-CoV-2 vaccine in patients living with HIV: The COVIH-DAPT study.

Manni S, Ruetsch C, Fabre R, Ticchioni M, Graca D, Pradier C Front Immunol. 2023; 14:1136723.

PMID: 36949938 PMC: 10025349. DOI: 10.3389/fimmu.2023.1136723.

Longitudinal COVID-19 immune trajectories in patients with neurological autoimmunity on anti-CD20 therapy.

Bazzi S, Maguire C, Holay N, Geltman J, Hurley K, DiPasquale C Mult Scler Relat Disord. 2022; 68:104195.

PMID: 36223705 PMC: 9511881. DOI: 10.1016/j.msard.2022.104195.

T Cell and Antibody Response Following Double Dose of BNT162b2 mRNA Vaccine in SARS-CoV-2 Naïve Heart Transplant Recipients.

Delrue L, Muylaert A, Beernaert A, De Pelsmaeker I, Boel E, Moya A Diagnostics (Basel). 2022; 12(9).

PMID: 36140549 PMC: 9497465. DOI: 10.3390/diagnostics12092148.

References
1.
Soresina A, Moratto D, Chiarini M, Paolillo C, Baresi G, Foca E . Two X-linked agammaglobulinemia patients develop pneumonia as COVID-19 manifestation but recover. Pediatr Allergy Immunol. 2020; 31(5):565-569. PMC: 7264678. DOI: 10.1111/pai.13263. View
2.
Andersen K, Rambaut A, Lipkin W, Holmes E, Garry R . The proximal origin of SARS-CoV-2. Nat Med. 2020; 26(4):450-452. PMC: 7095063. DOI: 10.1038/s41591-020-0820-9. View
3.
Liu L, Wei Q, Lin Q, Fang J, Wang H, Kwok H . Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection. JCI Insight. 2019; 4(4). PMC: 6478436. DOI: 10.1172/jci.insight.123158. View
4.
Hughes R, Pedotti R, Koendgen H . COVID-19 in persons with multiple sclerosis treated with ocrelizumab - A pharmacovigilance case series. Mult Scler Relat Disord. 2020; 42:102192. PMC: 7228884. DOI: 10.1016/j.msard.2020.102192. View
5.
Lund F . Cytokine-producing B lymphocytes-key regulators of immunity. Curr Opin Immunol. 2008; 20(3):332-8. PMC: 2474694. DOI: 10.1016/j.coi.2008.03.003. View